Trastuzumab Deruxtecan: 14 agencies, 2020–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain) has been harder on trastuzumab deruxtecan than on its own caseload: it refused 10 of 12 decisive submissions here (83%), against a base rate of 63% across everything it has assessed.
Assessment has run over 6.4 years, from 13 May 2020 at CHUIKYO (Japan) to 7 Oct 2026 at NICE (England).
AOTMIT (Poland) changed its position: not recommended on 27 Dec 2022, restricted by 26 Jun 2025, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for trastuzumab deruxtecan, 4 submissions were never made and 3 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 53 of 64 records date from 2023 or later.
The programme is broad: 15 distinct indication wordings are recorded for trastuzumab deruxtecan by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 64 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
CHUIKYO (Japan) was first to assess trastuzumab deruxtecan, on 13 May 2020; HIRA (South Korea) did not open a file until 11 Jan 2024 — a wide spread of 3.7 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 7 years in total.
13 of the 14 agencies here assessed trastuzumab deruxtecan more than once, CIPM (Spain) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
trastuzumab deruxtecan has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for trastuzumab deruxtecan reads 22 recommended, 16 not recommended, 8 restricted and 4 non-submission, with 14 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 22 Sep 2026 | Advies - alleen vergoeden na prijsdaling trastuzumab-deruxtecan (Enhertu®) voor de behandeling van niet-kleincellige lon… | reimburse only after price negotiation (sluis) | source |
| HAS (France) | 15 Apr 2026 | Indication extension | ASMR IV | source |
| G-BA (Germany) | 19 Mar 2026 | Enhertu — benefit assessment §35a | added benefit: minor (indication) | source |
| CIPM (Spain) | 25 Feb 2026 | Indicaciones terapéuticas autorizadas: Cáncer de mama Cáncer de mama HER2-positivo Enhertu en monoterapia está indicado … | not financed by the SNS · art. 92 d | source |
| DMC (Denmark) | 19 Feb 2026 | T-DXd til metastatisk HER2-lav brystkræft | Anbefalet | source |
59 further decisions for trastuzumab deruxtecan, across 14 agencies, are not shown here. They include the most recent record on file, 7 Oct 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 51 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 64 decisions for trastuzumab deruxtecan from 14 agencies, 2020 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.